Cargando…

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer

Trastuzumab is established as standard care for patients with HER2-positive breast cancer both in the adjuvant and metastatic setting. However, 50% of the patients do not respond to the trastuzumab therapy, and therefore new predictive biomarkers are highly warranted. MicroRNAs (miRs) constitute a n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nielsen, Boye Schnack, Balslev, Eva, Poulsen, Tim Svenstrup, Nielsen, Dorte, Møller, Trine, Mortensen, Christiane Ehlers, Holmstrøm, Kim, Høgdall, Estrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133651/ https://www.ncbi.nlm.nih.gov/pubmed/25177545 http://dx.doi.org/10.3389/fonc.2014.00207

Ejemplares similares

Mucosal expression of PI3, ANXA1, and VDR discriminates Crohn’s disease from ulcerative colitis
por: James, Jaslin Pallikkunnath, et al.
Publicado: (2023)

Potential Targeted Therapies in Ovarian Cancer
por: Sisman, Yagmur, et al.
Publicado: (2022)

Co-Detection of miR-21 and TNF-α mRNA in Budding Cancer Cells in Colorectal Cancer
por: Møller, Trine, et al.
Publicado: (2019)

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
por: Sisman, Yagmur, et al.
Publicado: (2022)

MicroRNA Biomarkers in IBD—Differential Diagnosis and Prediction of Colitis-Associated Cancer
por: James, Jaslin P., et al.
Publicado: (2020)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

The prevalence of EBV and CMV DNA in epithelial ovarian cancer
por: Ingerslev, Kasper, et al.
Publicado: (2019)

High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients
por: Nielsen, Boye Schnack, et al.
Publicado: (2010)

Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing
por: Poulsen, Tim S., et al.
Publicado: (2013)

Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures
por: Oliveira, Douglas V. N. P., et al.
Publicado: (2021)

High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population
por: Ingerslev, Kasper, et al.
Publicado: (2016)

The impact of metabolic supply lines - and the patterns between them - on the development of distant metastases in 64 women with breast cancer
por: Abrahamsen, Oliver, et al.
Publicado: (2022)

The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis
por: Ingerslev, Kasper, et al.
Publicado: (2017)

Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour
por: Brinch, Charlotte, et al.
Publicado: (2021)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

miR-21 expression analysis in budding colon cancer cells by confocal slide scanning microscopy
por: Knudsen, Kirsten Nguyen, et al.
Publicado: (2018)

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020)

DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis
por: Plougmann, Julie Isabelle, et al.
Publicado: (2019)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
por: Demuth, Christina, et al.
Publicado: (2018)

Evidence of No Association Between Human Papillomavirus and Breast Cancer
por: Bønløkke, Sara, et al.
Publicado: (2018)

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan
por: Schou, Jakob V., et al.
Publicado: (2014)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study
por: Hansen, Torben Frøstrup, et al.
Publicado: (2015)

Inactivating BTK mutations in large B‐cell lymphoma in a real‐world cohort: Strong correlation with BCL2 translocation
por: Schejbel, Lone, et al.
Publicado: (2022)

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
por: Kümler, Iben, et al.
Publicado: (2015)

MicroRNA-200b is downregulated in colon cancer budding cells
por: Knudsen, Kirsten Nguyen, et al.
Publicado: (2017)

Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus
por: Vestergaard, Lau K., et al.
Publicado: (2021)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project
por: Hentze, Julie L., et al.
Publicado: (2017)

Monocyte Infiltration and Differentiation in 3D Multicellular Spheroid Cancer Models
por: Madsen, Natasha Helleberg, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer
por: Aboutorabi, Ali, et al.
Publicado: (2015)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study
por: Ørtoft, Gitte, et al.
Publicado: (2019)

Extracellular Proteolysis in Transgenic Mouse Models of Breast Cancer
por: Almholt, Kasper, et al.
Publicado: (2007)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

MicroRNA characteristics in epithelial ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2021)

Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer
por: Gilbert, Duncan C, et al.
Publicado: (2016)

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol
por: Spindler, Nicklas Juel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ef87rj1nfahe9pmn0ofl8mbs2c